Clinical Readouts From CB-010, an Allogeneic Genome-Edited Anti-CD19 CAR-T Cell Therapy
Time: 11:45 am
day: Day 2 Track B AM
Details:
- Utilizing chRDNA genome-editing technology to engineer more precise genome edits
- Developing armoring strategies that improve antitumor response in allogeneic CAR-T cell therapies
- Reporting safety and efficacy dose escalation data from the ongoing CB-010 ANTLER Phase 1 trial
